<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2758">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05586750</url>
  </required_header>
  <id_info>
    <org_study_id>2006611</org_study_id>
    <nct_id>NCT05586750</nct_id>
  </id_info>
  <brief_title>Statins in Reducing Events in the Elderly Mind (STAREE-Mind) Imaging Substudy</brief_title>
  <acronym>STAREE-Mind</acronym>
  <official_title>Clinical Trial to Determine the Effects of Statins on Brain Health - STAREE-Mind Imaging Substudy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Monash University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The STAREE-Mind imaging sub-study will examine the effect of statin treatment over a 4-year&#xD;
      period, compared with placebo, on markers of brain health.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STAREE-Mind imaging is a sub-study nested in the Statins in Reducing Events in the Elderly&#xD;
      (STAREE) double blind randomised placebo-controlled trial. STAREE is investigating whether&#xD;
      statins can prolong good health and maintain independence amongst older people and is&#xD;
      enrolling. STAREE-Mind imaging aims to recruit a sub-group of 340 participants, and will&#xD;
      involve an additional suite of brain imaging in these participants, at recruitment (before&#xD;
      medication is commenced) and at 4 years follow-up. It will provide crucial information about&#xD;
      the clinical effects of statins on brain health in older individuals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2019</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Free water</measure>
    <time_frame>Change from baseline to four years</time_frame>
    <description>Multi-compartment free water quantitation from brain diffusion-weighted MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peri-vascular space volume</measure>
    <time_frame>Change from baseline to four years</time_frame>
    <description>From brain T1-weighted MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>White matter hyperintensity volume</measure>
    <time_frame>Change from baseline to four years</time_frame>
    <description>From brain FLAIR MRI</description>
  </primary_outcome>
  <other_outcome>
    <measure>Cortical thickness</measure>
    <time_frame>Change from baseline to four years</time_frame>
    <description>Cortical thickness as measured by T1-weighted structural MRI.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hippocampal volume</measure>
    <time_frame>Change from baseline to four years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Microbleeds and lacunae</measure>
    <time_frame>Change from baseline to four years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Prefrontal cortex cerebral perfusion</measure>
    <time_frame>Change from baseline to four years</time_frame>
    <description>Prefrontal cortex cerebral perfusion as measured by pseudo-continuous arterial spin labelling (pCASL) MRI.</description>
  </other_outcome>
  <other_outcome>
    <measure>Whole-brain white matter fractional anisotropy</measure>
    <time_frame>Change from baseline to four years</time_frame>
    <description>Whole-brain white matter fractional anisotropy as measured by diffusion-weighted imaging (DWI) MRI.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Dementia, Mixed</condition>
  <condition>Dementia, Vascular</condition>
  <condition>Dementia of Alzheimer Type</condition>
  <condition>Cognitive Decline</condition>
  <condition>White Matter Hyperintensity</condition>
  <condition>Aging</condition>
  <condition>Neuro-Degenerative Disease</condition>
  <arm_group>
    <arm_group_label>STAREE Statin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>STAREE Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 40 Mg Oral Tablet</intervention_name>
    <description>40 mg atorvastatin (2 x 20 mg atorvastatin daily), taken orally</description>
    <arm_group_label>STAREE Statin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 x 20mg placebo (daily), taken orally. Identical appearance to study drug</description>
    <arm_group_label>STAREE Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants in the STAREE RCT and eligible for randomisation to study medication.&#xD;
&#xD;
          -  Men and women&#xD;
&#xD;
          -  Aged â‰¥70 years&#xD;
&#xD;
          -  Living independently in the community&#xD;
&#xD;
          -  Willing and able to provide informed consent and agree to participate in brain&#xD;
             neuroimaging.&#xD;
&#xD;
          -  Able to attend one of the 2 sites (in Melbourne and Brisbane) where the imaging will&#xD;
             take place.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to have magnetic resonance neuroimaging performed.&#xD;
&#xD;
          -  History of invasive brain surgery or known structural bran abnormalities.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophia Zoungas, MBBS, FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanne Ryan, PhD</last_name>
    <phone>399030200</phone>
    <phone_ext>+61</phone_ext>
    <email>joanne.ryan@monash.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ian Harding, PhD</last_name>
    <phone>3 9905 9283</phone>
    <phone_ext>+61</phone_ext>
    <email>ian.harding@monash.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herston Imaging Research Facility (HIRF)</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maddy Lee</last_name>
      <phone>736465825</phone>
      <email>madeleine.lee@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Michael O'Sullivan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herston Imaging Research Facility (HIRF)</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael O'Sullivan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Biomedical Imaging (MBI)</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kylie Reid, BSc</last_name>
      <phone>399029782</phone>
      <phone_ext>+61</phone_ext>
      <email>kylie.reid@monash.edu</email>
    </contact>
    <contact_backup>
      <last_name>Louise Mitchell</last_name>
      <phone>0399029779</phone>
      <email>louise.mitchell@monash.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ian Harding, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Biomedical Imaging (MBI)</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ian Harding, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>October 10, 2022</study_first_submitted>
  <study_first_submitted_qc>October 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2022</study_first_posted>
  <last_update_submitted>October 15, 2022</last_update_submitted>
  <last_update_submitted_qc>October 15, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Monash University</investigator_affiliation>
    <investigator_full_name>Joanne Ryan</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>White matter mean diffusivity</keyword>
  <keyword>Perivascular space</keyword>
  <keyword>Free water</keyword>
  <keyword>White matter hyperintensity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After publication of the trial outcomes, the de-identified data will be available to approved researchers through a secure portal.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

